Loading...

Berenson James L

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentMedicine
AddressVA WADS
Los Angeles CA 90095
Phone268-3622
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Rahbari KJ, Nosrati JD, Spektor TM, Berenson JR. Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 Jun 18. PMID: 30033209.
      View in: PubMed
    2. Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018 May 31. PMID: 29866475.
      View in: PubMed
    3. Gross Z, Rahbari A, Wirtschafter E, Spektor TM, Udd KA, Bujarski S, Ghermezi M, Nosrati JD, Vidisheva A, Eades B, Cecchi G, Maluso T, Swift R, Berenson JR. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study. Eur J Haematol. 2018 Mar 10. PMID: 29524348.
      View in: PubMed
    4. Sanchez E, Tanenbaum EJ, Patil S, Li M, Soof CM, Vidisheva A, Waterman GN, Hekmati T, Tang G, Wang CS, Chen H, Berenson J. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018 Apr; 18(4):319-329. PMID: 29504446.
      View in: PubMed
    5. Sanchez E, Smith EJ, Yashar MA, Patil S, Li M, Porter AL, Tanenbaum EJ, Schlossberg RE, Soof CM, Hekmati T, Tang G, Wang CS, Chen H, Berenson JR. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma. Target Oncol. 2018 Feb; 13(1):39-47. PMID: 29230672.
      View in: PubMed
    6. Udd KA, Spektor TM, Berenson JR. Monitoring multiple myeloma. Clin Adv Hematol Oncol. 2017 Dec; 15(12):951-961. PMID: 29315287.
      View in: PubMed
    7. Cohen A, Spektor TM, Stampleman L, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Y, Maluso T, Swift RA, Vescio R, Berenson JR. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. Br J Haematol. 2018 01; 180(1):60-70. PMID: 29164606.
      View in: PubMed
    8. Boccia RV, Bessudo A, Agajanian R, Conkling P, Harb W, Yang H, Pinchasik D, Kimball AS, Berenson JR. A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2). Clin Lymphoma Myeloma Leuk. 2017 07; 17(7):433-437. PMID: 28576443.
      View in: PubMed
    9. Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, Berenson JR. Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Support Care Cancer. 2017 10; 25(10):3217-3224. PMID: 28455546.
      View in: PubMed
    10. Berenson J, Manges R, Badarinath S, Cartmell A, McIntyre K, Lyons R, Harb W, Mohamed H, Nourbakhsh A, Rifkin R. A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. Am J Hematol. 2017 May; 92(5):460-466. PMID: 28213943.
      View in: PubMed
    11. Sanchez E, Li M, Wang CS, Tang G, Gillespie A, Chen H, Berenson JR. Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex). Leuk Res. 2017 06; 57:45-54. PMID: 28288323.
      View in: PubMed
    12. Chen H, Li M, Sanchez E, Wang CS, Lee T, Soof CM, Casas CE, Cao J, Xie C, Udd KA, DeCorso K, Tang GY, Spektor TM, Berenson JR. Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects. Mol Cancer Res. 2017 May; 15(5):598-609. PMID: 28122920.
      View in: PubMed
    13. Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Spektor TM, Andreu-Vieyra C, Petraki S, Sanchez E, Udd K, Wang CS, Swift RA, Chen H, Berenson JR. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017 04; 102(4):785-795. PMID: 28034989.
      View in: PubMed
    14. Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. Ann Hematol. 2017 Mar; 96(3):449-459. PMID: 27933373.
      View in: PubMed
    15. Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Ann Hematol. 2017 Mar; 96(3):441-448. PMID: 27913860.
      View in: PubMed
    16. Pogue SL, Taura T, Bi M, Yun Y, Sho A, Mikesell G, Behrens C, Sokolovsky M, Hallak H, Rosenstock M, Sanchez E, Chen H, Berenson J, Doyle A, Nock S, Wilson DS. Targeting Attenuated Interferon-a to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity. PLoS One. 2016; 11(9):e0162472. PMID: 27611189; PMCID: PMC5017640.
    17. Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016 06 30; 127(26):3360-8. PMID: 27207788; PMCID: PMC4929927.
    18. Harutyunyan NM, Vardanyan S, Ghermezi M, Gottlieb J, Berenson A, Andreu-Vieyra C, Berenson JR. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients. Br J Haematol. 2016 07; 174(1):81-7. PMID: 27017948.
      View in: PubMed
    19. Sanchez E, Gillespie A, Tang G, Ferros M, Harutyunyan NM, Vardanyan S, Gottlieb J, Li M, Wang CS, Chen H, Berenson JR. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Clin Cancer Res. 2016 Jul 01; 22(13):3383-97. PMID: 26960399.
      View in: PubMed
    20. Robinson AA, Wang J, Vardanyan S, Madden EK, Hebroni F, Udd KA, Spektor TM, Nosrati JD, Kitto AZ, Zahab M, Cheema S, Fors DH, Norberg A, Diehl J, Waterman GN, Swift RA, Crowley J, Berenson JR. Risk of skin cancer in multiple myeloma patients: a retrospective cohort study. Eur J Haematol. 2016 Nov; 97(5):439-444. PMID: 26872804.
      View in: PubMed
    21. Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, Ibrahim E, Treisman J, Masri M, Berenson JR. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Support Care Cancer. 2016 07; 24(7):3105-10. PMID: 26902977.
      View in: PubMed
    22. Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst. 2016 Mar; 108(3). PMID: 26582244.
      View in: PubMed
    23. Berenson JR, Andreu-Vieyra C. Counterpoints: Do patients with multiple myeloma need maintenance treatment? Yes, but the proper candidates and schedule must be determined. Clin Adv Hematol Oncol. 2015 Mar; 13(3):163-6. PMID: 26352423.
      View in: PubMed
    24. Berenson JR. Bone-targeted therapies for cancer patients and bone cell biology: where do we stand? Curr Opin Support Palliat Care. 2014 Dec; 8(4):405-6. PMID: 25319276.
      View in: PubMed
    25. Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol. 2014 Dec; 5(6):197-210. PMID: 25469210; PMCID: PMC4250267.
    26. Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, Sanani S, Schlutz M, Nassir Y, Swift RA, Andreu-Vieyra C, Vescio R. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Support Care Cancer. 2015 Jun; 23(6):1503-12. PMID: 25370889.
      View in: PubMed
    27. Andreu-Vieyra C, Berenson JR. Carfilzomib in multiple myeloma. Expert Opin Biol Ther. 2014 Nov; 14(11):1685-99. PMID: 25170966.
      View in: PubMed
    28. Huerta-Yepez S, Liu H, Baritaki S, Del Lourdes Cebrera-Muñoz M, Rivera-Pazos C, Maldonado-Valenzuela A, Valencia-Hipolito A, Vega MI, Chen H, Berenson JR, Bonavida B. Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance. Int J Oncol. 2014 Sep; 45(3):1184-92. PMID: 24970600.
      View in: PubMed
    29. Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014 Aug 14; 124(7):1047-55. PMID: 24904120; PMCID: PMC4468583.
    30. Sanchez E, Chen H, Berenson JR. In vivo models of multiple myeloma (MM). Biochem Pharmacol. 2014 Jun 01; 89(3):313-20. PMID: 24704250.
      View in: PubMed
    31. Terpos E, Berenson J, Raje N, Roodman GD. Management of bone disease in multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):113-25. PMID: 24433088.
      View in: PubMed
    32. Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014 Jan 30; 123(5):632-9. PMID: 24335104; PMCID: PMC4123425.
    33. Berenson JR. Cryoglobulinemia: better treatments with brighter outcomes. Oncology (Williston Park). 2013 Nov; 27(11):1125-6, 1128. PMID: 24575540.
      View in: PubMed
    34. Berenson JR. Multiple myeloma: treatment updates. Clin Adv Hematol Oncol. 2013 Nov; 11(11):744-5. PMID: 24896549.
      View in: PubMed
    35. Berenson JR, Hilger JD, Yellin O, Boccia RV, Matous J, Dressler K, Ghazal HH, Jamshed S, Kingsley EC, Harb WA, Noga SJ, Nassir Y, Swift RA, Vescio R. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol. 2014 Jan; 93(1):89-98. PMID: 24135804.
      View in: PubMed
    36. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol. 2013 Feb; 160(3):321-30. PMID: 23150919.
      View in: PubMed
    37. Berenson JR. Updates in the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2012 Oct; 10(10):667-9. PMID: 23187773.
      View in: PubMed
    38. Eshaghian S, Berenson JR. Multiple myeloma: improved outcomes with new therapeutic approaches. Curr Opin Support Palliat Care. 2012 Sep; 6(3):330-6. PMID: 22871979.
      View in: PubMed
    39. Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leuk Res. 2012 Nov; 36(11):1422-7. PMID: 22906694.
      View in: PubMed
    40. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012 Sep; 158(6):727-38. PMID: 22804669.
      View in: PubMed
    41. Sanchez E, Li M, Wang C, Nichols CM, Li J, Chen H, Berenson JR. Anti-myeloma effects of the novel anthracycline derivative INNO-206. Clin Cancer Res. 2012 Jul 15; 18(14):3856-67. PMID: 22619306.
      View in: PubMed
    42. Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B. TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):155-63. PMID: 22440007; PMCID: PMC3799862.
    43. Berenson JR, Yellin O, Chen CS, Patel R, Bessudo A, Boccia RV, Yang HH, Vescio R, Yung E, Mapes R, Eades B, Hilger JD, Wirtschafter E, Hilger J, Nassir Y, Swift RA. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol. 2011 Dec; 155(5):580-7. PMID: 21950583.
      View in: PubMed
    44. Waterman GN, Yellin O, Jamshidinia K, Swift RA, Tamkin JA, Audell RA, Berenson JR. Metatarsal stress fractures in patients with multiple myeloma treated with long-term bisphosphonates: a report of six cases. J Bone Joint Surg Am. 2011 Sep 21; 93(18):e106. PMID: 21938357.
      View in: PubMed
    45. Berenson JR. Antitumor effects of bisphosphonates: from the laboratory to the clinic. Curr Opin Support Palliat Care. 2011 Sep; 5(3):233-40. PMID: 21825999.
      View in: PubMed
    46. Berenson JR, Yellin O, Quiery A, Brady J, Patel R, Wong SF, Colbourn D, Gravenor D, Tiffany N, Shamasunder HK, Waterman B, Melamed K, Wirtschafter E. A retrospective study to evaluate the work-up and follow-up of patients with monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):336-41. PMID: 21816371.
      View in: PubMed
    47. Berenson JR. The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Feb; 12(1):2-4. PMID: 22130220.
      View in: PubMed
    48. Baritaki S, Huerta-Yepez S, Cabrava-Haimandez MD, Sensi M, Canevari S, Libra M, Penichet M, Chen H, Berenson JR, Bonavida B. Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. For Immunopathol Dis Therap. 2011 Apr 01; 2(2). PMID: 24286018.
      View in: PubMed
    49. Berenson J, Pflugmacher R, Jarzem P, Zonder J, Schechtman K, Tillman JB, Bastian L, Ashraf T, Vrionis F. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011 Mar; 12(3):225-35. PMID: 21333599.
      View in: PubMed
    50. Terpos E, Dimopoulos MA, Berenson J. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Crit Rev Oncol Hematol. 2011 Feb; 77 Suppl 1:S13-23. PMID: 21353176.
      View in: PubMed
    51. Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein N, Bolejack V, Nassir Y, Hilger JD, Sefaradi A, Shamouelian A, Swift RA. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. Am J Hematol. 2011 Jan; 86(1):25-30. PMID: 21120861.
      View in: PubMed
    52. Berenson JR, Boccia R, Lopez T, Warsi GM, Argonza-Aviles E, Lake S, Ericson SG, Collins R. Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). J Support Oncol. 2011 Jan-Feb; 9(1):32-40. PMID: 21465735.
      View in: PubMed
    53. Waterman GN, Yellin O, Swift RA, Mapes R, Eades B, Ackerman E, Berenson JR. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Ann Hematol. 2011 Feb; 90(2):193-200. PMID: 20809423.
      View in: PubMed
    54. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res. 2011 Mar; 35(3):373-9. PMID: 20650529.
      View in: PubMed
    55. Chen H, Wang CS, Li M, Sanchez E, Li J, Berenson A, Wirtschafter E, Wang J, Shen J, Li Z, Bonavida B, Berenson JR. A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay. Int J Oncol. 2010 Jul; 37(1):71-9. PMID: 20514398.
      View in: PubMed
    56. Berenson JR. Therapeutic options in the management of myeloma bone disease. Semin Oncol. 2010 Jun; 37 Suppl 1:S20-9. PMID: 20682368.
      View in: PubMed
    57. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul; 150(1):28-38. PMID: 20507313.
      View in: PubMed
    58. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010 May; 95(5):845-8. PMID: 20133895; PMCID: PMC2864394.
    59. Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J. The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk. 2010 Feb; 10(1):28-43. PMID: 20223727.
      View in: PubMed
    60. Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B, Li ZW, Chen H, Berenson JR. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol. 2010 Feb; 148(4):569-81. PMID: 19958357.
      View in: PubMed
    61. Campbell RA, Sanchez E, Steinberg J, Shalitin D, Li ZW, Chen H, Berenson JR. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol. 2010 Mar; 84(3):201-11. PMID: 19929977.
      View in: PubMed
    62. Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res. 2009 Nov 01; 69(21):8376-85. PMID: 19843864.
      View in: PubMed
    63. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23; 114(4):772-8. PMID: 19471019.
      View in: PubMed
    64. Berenson JR. Hematology: Bortezomib in newly diagnosed multiple myeloma. Nat Rev Clin Oncol. 2009 May; 6(5):255-6. PMID: 19390550.
      View in: PubMed
    65. Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, Eades B, Abaya CD, Hilger J, Swift RA. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol. 2009 Jun; 82(6):433-9. PMID: 19226361.
      View in: PubMed
    66. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, Swift RA. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2009 Feb 01; 15(3):1069-75. PMID: 19188182.
      View in: PubMed
    67. Chen H, Campbell RA, Chang Y, Li M, Wang CS, Li J, Sanchez E, Share M, Steinberg J, Berenson A, Shalitin D, Zeng Z, Gui D, Perez-Pinera P, Berenson RJ, Said J, Bonavida B, Deuel TF, Berenson JR. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood. 2009 Feb 26; 113(9):1992-2002. PMID: 19060246; PMCID: PMC2651013.
    68. Bashey A, Pérez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008 Oct; 14(10):1118-1124. PMID: 18804041; PMCID: PMC2584240.
    69. Berenson JR, Yellin O, Boccia RV, Flam M, Wong SF, Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y, Swift RA. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin Cancer Res. 2008 Oct 01; 14(19):6289-95. PMID: 18829511.
      View in: PubMed
    70. Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov; 143(4):537-40. PMID: 18783399.
      View in: PubMed
    71. Berenson JR, Yellin O. New drugs in multiple myeloma. Curr Opin Support Palliat Care. 2008 Sep; 2(3):204-10. PMID: 18685422.
      View in: PubMed
    72. Wang Q, Zheng JY, Kreth J, Yan X, Kamata M, Campbell RA, Xie Y, Chiu R, Berenson JR, Shi W, Chen IS, Pang S. Regulation of prostate-specific antigen expression by the junctional adhesion molecule A. Urology. 2009 May; 73(5):1119-25. PMID: 18602143.
      View in: PubMed
    73. Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR. NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol. 2008 Jul; 15(4):391-9. PMID: 18536579.
      View in: PubMed
    74. Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol. 2008 Aug; 87(8):623-31. PMID: 18463870.
      View in: PubMed
    75. Perez-Pinera P, Berenson JR, Deuel TF. Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis. Curr Opin Hematol. 2008 May; 15(3):210-4. PMID: 18391787.
      View in: PubMed
    76. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol. 2008 May 01; 180(9):6199-210. PMID: 18424742; PMCID: PMC3747671.
    77. Campbell RA, Berenson JR. Animal models of multiple myeloma and their utility in drug discovery. Curr Protoc Pharmacol. 2008 Mar; Chapter 14:Unit 14.9. PMID: 22294221.
      View in: PubMed
    78. Berenson JR. Proteasome inhibitors: closing the garbage can opens up new therapeutic options for patients with B-cell malignancies. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S182-3. PMID: 17877842.
      View in: PubMed
    79. Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson JR. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol. 2007 Aug; 138(4):467-78. PMID: 17587338.
      View in: PubMed
    80. Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B, Berenson JR. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood. 2007 Jul 01; 110(1):287-95. PMID: 17369488.
      View in: PubMed
    81. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007 Mar 15; 13(6):1762-8. PMID: 17363530.
      View in: PubMed
    82. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma. 2007 Mar; 7(5):346-53. PMID: 17562244.
      View in: PubMed
    83. Berenson JR, Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma. 2006 Nov; 7(3):192-8. PMID: 17229334.
      View in: PubMed
    84. Yeh HS, Berenson JR. Treatment for myeloma bone disease. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6279s-6284s. PMID: 17062714.
      View in: PubMed
    85. Zheng J, Xie Y, Campbell R, Song J, Wang RQ, Chiu R, Berenson J, Razi M, Massachi S, Yang OO, Chen IS, Pang S. gp120-independent HIV infection of cells derived from the female reproductive tract, brain, and colon. J Acquir Immune Defic Syndr. 2006 Oct 01; 43(2):127-36. PMID: 16951651.
      View in: PubMed
    86. Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh HS, Swift RA. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006 Oct; 135(2):174-83. PMID: 17010047.
      View in: PubMed
    87. Berenson JR, Rajdev L, Broder M. Pathophysiology of bone metastases. Cancer Biol Ther. 2006 Sep; 5(9):1078-81. PMID: 17012831.
      View in: PubMed
    88. Berenson JR, Rajdev L, Broder M. Treatment strategies for skeletal complications of cancer. Cancer Biol Ther. 2006 Sep; 5(9):1074-7. PMID: 16969118.
      View in: PubMed
    89. Berenson JR, Rajdev L, Broder M. Bone complications in multiple myeloma. Cancer Biol Ther. 2006 Sep; 5(9):1082-5. PMID: 16969119.
      View in: PubMed
    90. Berenson JR, Rajdev L, Broder M. Managing bone complications of solid tumors. Cancer Biol Ther. 2006 Sep; 5(9):1086-9. PMID: 16969120.
      View in: PubMed
    91. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul; 91(7):929-34. PMID: 16818280.
      View in: PubMed
    92. Yeh HS, Berenson JR. Myeloma bone disease and treatment options. Eur J Cancer. 2006 Jul; 42(11):1554-63. PMID: 16797971.
      View in: PubMed
    93. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 01; 24(19):3113-20. PMID: 16754936.
      View in: PubMed
    94. Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, Popoviciu L, Wang C, Gordon M, Pang S, Bonavida B, Said J, Berenson JR. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol. 2006 Jun; 28(6):1409-17. PMID: 16685443.
      View in: PubMed
    95. Yeh HS, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Lee HJ, Waterman G, Gordon MS, Ma J, Bonavida B, Berenson JR. Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. Br J Haematol. 2006 Jun; 133(5):526-9. PMID: 16681640.
      View in: PubMed
    96. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer. 2006 Mar 15; 106(6):1316-9. PMID: 16470606.
      View in: PubMed
    97. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006 Feb 20; 24(6):937-44. PMID: 16418495.
      View in: PubMed
    98. Zheng J, Xie Y, Campbell R, Song J, Massachi S, Razi M, Chiu R, Berenson J, Yang OO, Chen IS, Pang S. Involvement of claudin-7 in HIV infection of CD4(-) cells. Retrovirology. 2005 Dec 20; 2:79. PMID: 16368003; PMCID: PMC1352390.
    99. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Nov 15; 104(10):2141-8. PMID: 16206291.
      View in: PubMed
    100. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005 Dec 01; 106(12):3777-84. PMID: 16099887; PMCID: PMC1895114.
    101. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Xiao H, Esseltine D, Schenkein D, Anderson KC. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005 Nov 01; 106(9):2977-81. PMID: 16020506.
      View in: PubMed
    102. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005 Mar 15; 103(6):1195-200. PMID: 15690325.
      View in: PubMed
    103. Berenson JR. Myeloma bone disease. Best Pract Res Clin Haematol. 2005; 18(4):653-72. PMID: 16026743.
      View in: PubMed
    104. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005 Jan; 10(1):52-62. PMID: 15632252.
      View in: PubMed
    105. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U, Norin AJ, Akman HO, Ozçelik T, Batuman OA. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005 Apr 15; 105(8):3286-94. PMID: 15618473.
      View in: PubMed
    106. Berenson JR, Swift RA, Ferretti D, Purner MB. A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. Clin Lymphoma. 2004 Sep; 5(2):130-4. PMID: 15453931.
      View in: PubMed
    107. Berenson JR. Supportive care in myeloma. Clin Adv Hematol Oncol. 2004 Sep; 2(9):569, 571. PMID: 16163246.
      View in: PubMed
    108. Feinman R, Siegel DS, Berenson J. Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol. 2004 Mar; 2(3):162-6. PMID: 16166946.
      View in: PubMed
    109. Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist. 2004; 9(3):319-29. PMID: 15169987.
      View in: PubMed
    110. Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. J Clin Oncol. 2003 Dec 01; 21(23 Suppl):246s-252s. PMID: 14645404.
      View in: PubMed
    111. Berenson JR. Treatment strategies for myeloma bone disease. Oncology (Williston Park). 2003 Dec; 17(12):1678, 1681-2. PMID: 14723007.
      View in: PubMed
    112. Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol. 2003 Nov 15; 21(22):4239-47. PMID: 14615454.
      View in: PubMed
    113. Yang HH, Vescio R, Schenkein D, Berenson JR. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymphoma. 2003 Sep; 4(2):119-22. PMID: 14556685.
      View in: PubMed
    114. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17. PMID: 12826635.
      View in: PubMed
    115. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003 Mar; 9(3):1136-44. PMID: 12631619.
      View in: PubMed
    116. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Ravera C, Schran H, Seaman J, Waldmeier F. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol. 2003 Feb; 43(2):154-62. PMID: 12616668.
      View in: PubMed
    117. Hahn T, Wingard JR, Anderson KC, Bensinger WI, Berenson JR, Brozeit G, Carver JR, Kyle RA, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003 Jan; 9(1):4-37. PMID: 12533739.
      View in: PubMed
    118. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol. 2002 Dec; 29(6 Suppl 21):12-8. PMID: 12584690.
      View in: PubMed
    119. Berenson JR. Advances in the biology and treatment of myeloma bone disease. Semin Oncol. 2002 Dec; 29(6 Suppl 17):11-6. PMID: 12520479.
      View in: PubMed
    120. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002 Nov; 42(11):1228-36. PMID: 12412821.
      View in: PubMed
    121. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002 Sep 01; 20(17):3719-36. PMID: 12202673.
      View in: PubMed
    122. Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M, Mikail A, Roussos E, Sjak-Shie N, Vescio RA, Berenson JR. Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet. 2002 Aug; 137(1):43-8. PMID: 12377412.
      View in: PubMed
    123. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002 May 01; 99(9):3163-8. PMID: 11964279.
      View in: PubMed